BMJ Open COVID-19 and children with congenital anomalies: a European survey of parents' experiences of healthcare services

Anna Latos-Bieleńska,¹ Elena Marcus ⁽¹⁾,² Anna Jamry-Dziurla,¹ Judith Rankin,³ Ingeborg Barisic,⁴ Clara Cavero- Carbonell ⁽¹⁾,⁵ Elly Den Hond,⁶ Ester Garne ⁽¹⁾,⁷ Lucas Genard,⁶ Ana João Santos,⁸ L Renée Lutke,⁹ Carlos Matias Dias,¹⁰ Christina Neergaard Pedersen,⁷ Amanda Neville,¹¹ Annika Niemann,¹² Ljubica Odak,⁴ Lucía Páramo-Rodríguez ⁽¹⁾,⁵ Anna Pierini,¹³ Anke Rissmann ⁽¹⁾,¹² Joan K Morris ⁽¹⁾,¹⁴

ABSTRACT

Objective To survey parents and carers of children with a congenital anomaly across Europe about their experiences of healthcare services and support during the COVID-19 pandemic.

Design Cross-sectional study.

Setting Online survey in 10 European countries, open from 8 March 2021 to 14 July 2021.

Population 1070 parents and carers of children aged 0–10 years with a cleft lip, spina bifida, congenital heart defect (CHD) requiring surgery and/or Down syndrome. **Main outcome measures** Parental views about: the provision of care for their child (cancellation/postponement of appointments, virtual appointments, access to medication), the impact of disruptions to healthcare on their child's health and well-being, and satisfaction with support from medical sources, organisations and close relationships.

Results Disruptions to healthcare appointments were significantly higher (p<0.001) in the UK and Poland, with approximately two-thirds of participants reporting 'cancelled or postponed' tests (67/101: 256/389) and procedures compared with approximately 20% in Germany (13/74) and Belgium/Netherlands (11/55). A third of participants in the UK and Poland reported 'cancelled or postponed' surgeries (22/72; 98/266) compared with only 8% in Germany (5/64). In Poland, 43% (136/314) of parents reported that changes to their child's ongoing treatment had moderately to severely affected their child's health, significantly higher than all other countries (p<0.001). Satisfaction ratings for support from general practitioners were lowest in the UK and Poland, and lowest in Poland and Italy for specialist doctors and nurses. **Conclusion** A large proportion of participants reported disruptions to healthcare during the pandemic, which for some had a significant impact on their child's health. Regional differences in disruptions raise guestions about the competence of certain healthcare systems to meet the needs of this vulnerable group of patients and indicate improvements should be strived for in some regions.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Surveys of the experiences of a large total number of parents and carers across several European countries and congenital anomaly (CA) types. The proportion of each CA type in the study sample reflects the relative number of live births with each CA in Europe.
- \Rightarrow High item-level response rates suggest that survey items were relevant to participants and easy to complete.
- ⇒ Potential bias in responses due to the use of social media for recruitment, for example, excluding people living with 'digital poverty' and those who do not engage with patient and parent organisations, limiting the generalisability of findings.
- ⇒ Inability to conduct a full pilot of the final survey to explore item acceptability, comprehension and relevance, possible that there may be some issues with the wording or content of items.

BACKGROUND

The COVID-19 pandemic put pressure on healthcare systems worldwide, causing severe disruptions to the delivery of non-essential services, as staff were redeployed to acute care, and outpatient treatment and follow-up were reduced due to concerns about viral transmission in hospital.^{1–3} Non-urgent elective care was the most heavily impacted, with a record backlog of 5.6 million cases reported in England in July 2021.⁴⁵

Congenital anomalies (CAs) are a range of conditions that are present from birth and remain a leading cause of childhood morbidity and long-term disability.⁶⁷ Children with CAs require regular clinical follow-up,⁸ including more frequent primary care appointments, hospital admissions and surgeries than

To cite: Latos-Bieleńska A, Marcus E, Jamry-Dziurla A, *et al.* COVID-19 and children with congenital anomalies: a European survey of parents' experiences of healthcare services. *BMJ Open* 2022;**12**:e061428. doi:10.1136/ bmjopen-2022-061428

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2022-061428).

AL-Bńs and EM contributed equally.

AL-Bńs and EM are joint first authors.

Received 25 January 2022 Accepted 20 May 2022

Check for updates

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Dr Elena Marcus; emarcus@sgul.ac.uk children without CAs.⁹⁻¹² Although children are less affected by SARS-CoV-2 infection than adults,¹³ Down syndrome has been indicated as a risk factor of severe disease and mortality,^{14 15} and children with underlying conditions may be at increased risk of infection.¹⁶ It is crucial to document the healthcare experiences of children with CAs during this period of increased pressure on healthcare systems, especially as they represent a vulnerable population. Existing research, conducted during the first wave of the pandemic in 2020, suggests a high proportion of cancellations and postponements to paediatric healthcare appointments and treatments in the USA¹⁷ and in Europe.^{18–22} Disruptions to the healthcare services of children with CAs were found to cause anxiety for parents,²⁰ and fear that their child's health may be negatively affected.²² Corcerns about SARS-CoV-2 infection were also common among parents,^{23 24} which coupled with reductions in other communicable infections during the pandemic,^{25 26} resulted in fewer visits to clinics^{25 27} and emergency departments^{26 28} in 2020. Parents reported a lack of support from healthcare professionals, including the absence of specific COVID-19-related guidance for children.^{22 29}

This paper describes a cross-sectional online survey, which explored the views of parents and carers of children with CAs about: (a) their healthcare experiences and (b) their experiences of support, 1 year into the pandemic. The survey was conducted as part of a collaborative European project, 'Establishing a linked European Cohort of Children with CAs (EUROlinkCAT)',³⁰ which aims to investigate health and educational outcomes in children born with CAs using population-based data. Due to differences in the level of restrictions, healthcare systems and the availability of resources between countries, the survey was conducted in several European countries, to explore possible variations in the provision of care.

METHODS

This study is reported following the Strengthening the Reporting of Observational studies in Epidemiology guidelines.³¹ The findings presented are a subsection of a cross-sectional online survey, conducted by the EUROlinkCAT team, which explored the wider information and support needs of parents and carers of children with CAs in 10 European countries. This paper focuses on the healthcare experiences and health status of children during the COVID-19 pandemic and parent and carer experiences of support. The survey was launched in the UK and Poland on 8 March 2021 and kept open until 14 July 2021. The survey was launched in a staggered manner in each country, as and when translations were finalised and approvals granted (table 1).

Participants

The survey was open to parents, carers and guardians (termed, henceforth, as *parents*) of children up to 10 years of age who have one or more of the following CAs: cleft

BMJ Open: first published as 10.1136/bmjopen-2022-061428 on 19 July 2022. Downloaded from http://bmjopen.bmj.com/ on July 26, 2022 at St George's, University of London. Protected by copyright.

lip (with or without a cleft palate), spina bifida, congenital heart defect (CHD) which required surgery and Down syndrome. Due to the high level of heterogeneity across all CAs, these groups were predefined and selected to cover different types of impairments, with likely differing impacts on the experiences of the child and parent: (a) physical disability (spina bifida), (b) learning disability (Down syndrome), (c) visible defects (cleft lip) and (d) non-visible defects (CHD). Participants were actively recruited in 10 European countries: Belgium, Croatia, Denmark, Germany, Italy, Netherlands, Poland, Portugal, Spain, and the UK.

Recruitment

Participants were recruited with convenience sampling which was conducted online via social media (Twitter and Facebook), charities and patient organisations within each participating country (eg, the Down Syndrome Association in the UK) and closed support groups on Facebook. Potential participants were provided with a link to the survey website, which included all language versions of the survey. Participants were provided with the participant information sheet at the start of the survey, and depending on local ethics requirements, participants were either required to complete an online consent form or consent was implied by completion of the survey. As the survey was shared across online platforms and by a number of international organisations (eg, Down Syndrome International), responses were also received from parents living in other European countries (eg, Ireland), and these were retained in the analysis.

Survey

The content of the survey was developed following a literature review, and input from expert clinicians, parents and educators, academics with expertise in CA research and questionnaire development and a Public Involvement and Community Engagement lead. The survey included the following sections: (1) Parent Demographics (nine items), (2) Child Demographics and Medical Information (seven items), (3) Provision of Healthcare (seven items), (4) Impact on the Child (three items) and (5) Support for Parents (two items) (see online supplemental file 1). Response options varied and comprised: yes and no (provision of healthcare); not at all, a little, quite a bit and very much (provision of healthcare); not at all satisfied, a little satisfied, quite satisfied and very satisfied (support for parents); and much worse, somewhat worse, about the same, somewhat better, much better (impact on child). All items were close ended; therefore, quantitative data only were collected. In relation to the timeframe, participants were asked to reflect on their experiences from the start of the pandemic in January 2020 to the time at which they completed the survey (March-July 2021).

Translation

The survey was developed in English and translated into eight European languages following existing guidance.³²

| Recruitment period† - 8 March 2021 8 March 20 Start date - 8 March 2021 8 March 20 End date - 14 July 2021 14 July 20 N 986 120 476 Age 120 162 (17%) 18 (15%) 93 (20%) 31-40 516 (53%) 53 (45%) 264 (56%) | | | | , | |
|--|------------------------|--------------------|--------------|---------------|-----------------|
| Start date – 8 March 2021 8 M End date – 14 July 2021 14 986 120 476 98 120 476 31-40 516 (53%) 53 (45%) 264 47 264 | | | | | |
| End date – 14 July 2021 14 986 120 476 98 120 476 31–40 516 (53%) 53 (45%) 266 416 416 417 418 (15%) 33 | larch 2021 11 May 2021 | 2021 26 April 2021 | 16 June 2021 | 19 April 2021 | 6 April 2021 |
| 986 120 Je ≤30 162 (17%) 18 (15%) 31–40 516 (53%) 53 (45%) | July 2021 14 July 2021 | 2021 14 July 2021 | 31 July 2021 | 14 July 2021 | 14 July 2021 |
| 162 (17%) 18 (15%) -40 516 (53%) 53 (45%) -40 201 (21%) 47 (40%) | 97 | 68 | 59 | 74 | 92 |
| 162 (17%) 18 (15%) 516 (53%) 53 (45%) 201 (2102) 47 (1022) | | | | | |
| 516 (53%) 53 (45%) | 6) 13 (13%) | 8 (12%) | 4 (7%) | 15 (20%) | 11 (12%) |
| | (%) 51 (53%) | 37 (55%) | 27 (46%) | 35 (47%) | 49 (53%) |
| 001 (01 70) 41 (40 70) | .%) 33 (34%) |) 22 (33%) | 28 (47%) | 24 (32%) | 34 (35%) |
| Relation to child | | | | | |
| Mother 911 (92%) 116 (97%) 449 (94%) | .%) 81 (84%) |) 63 (93%) | 52 (88%) | 64 (86%) | 86 (95%) |
| Father 65 (7%) 2 (2%) 24 (5%) | 13 (13%) |) 5 (7%) | 6 (10%) | 10 (14%) | 5 (5%) |
| Other‡ 8 (1%) 1 (1%) 3 (1%) | 3 (3%) | I | 1 (2%) | 1 | 1 |
| Employment | | | | | |
| Employed 586 (60%) 81 (68%) 223 (47%) | (%) 61 (62%) |) 54 (79%) | 44 (75%) | 61 (82%) | 62 (69%) |
| Homemaker/carer 301 (31%) 36 (30%) 198 (42%) | (%) 27 (29%) | 7 (10%) | 11 (19%) | 8 (11%) | 14 (16%) |
| Other§ 94 (9%) 3 (3%) 52 (11%) | (%6) 6 (%) | 7 (10%) | 4 (7%) | 5 (7%) | 14 (16%) |
| Education | | | | | |
| School≤18 years 390 (40%) 44 (37%) 163 (35%) | (%) 61 (67%) | 19 (28%) | 30 (52%) | 44 (60%) | 29 (32%) |
| University 482 (49%) 50 (42%) 257 (53%) | (%) 27 (29%) |) 45 (66%) | 19 (33%) | 29 (39%) | 55 (60%) |
| Post-graduate 106 (11%) 25 (21%) 56 (11%) | 6) 3 (3%) | 4 (6%) | 9 (16%) | 1 (1%) | 8 (9%) |
| Migrant status | | | | | |
| >10 years/from birth 924 (94%) 111 (93%) 467 (98%) | (%) 86 (88%) |) 64 (94%) | 50 (86%) | 71 (96%) | 75 (81%) |
| 6-10 years 30 (3%) 5 (4%) 5 (1%) | 6 (7%) | 2 (3%) | 4 (7%) | 1 (1%) | 7 (8%) |
| 1–5 years 28 (3%) 4 (3%) 2 (0.4%) | 5 (5% | 2 (3%) | 4 (7%) | 2 (3%) | 9 (10%) |
| <1 year 2 (0.2%) - 1 (0.2%) | - (9 | I | I | I | 1 (1%) |

6

Open access

BMJ Open: first published as 10.1136/bmjopen-2022-061428 on 19 July 2022. Downloaded from http://bmjopen.bmj.com/ on July 26, 2022 at St George's, University of London. Protected by copyright.

The Dutch version was used in Belgium and the Netherlands. The survey was initially translated into Polish and Italian to check for any translatability issues, and relevant amendments were subsequently made to the English version accordingly. These languages were selected because they have different origins (Slavic and Romance) with differing translation issues, and the research team included native Polish (AL-B, AJ-D) and native English-Italian bilingual (EM) speakers. Translations were carried out in four steps for each language version: (1) a native speaker of the target language with good command of English conducted the initial translation, (2) the translation was checked by at least one other native speaker of the target language and any problems discussed and reconciled, (3) the survey was back-translated by a native English speaker (or person with a good command of the English language) and who was naïve to the original version, (4) the back-translated survey was reviewed by EM against the original English language version and any semantic or conceptual discrepancies in the backtranslation were flagged and discussed with the translators until they were resolved. Due to differences in education systems across Europe, equivalent terminology for participants' education level was not available, and categories were selected to reflect local education systems within each country.

Data collection

Study data were collected and managed using Research Electronic Data Capture³³ tools hosted at St George's, University of London. All data collected were anonymous and it was, therefore, not possible to verify CA diagnoses. To keep the survey fully anonymous, no internet protocol addresses were collected, so it was not possible to prevent multiple participation. Participants were initially allowed to skip any item, however, following an interim analysis on 27 April 2021, a high proportion of missing data for country and CA type was noted. As these data were crucial to the research question, these two items were subsequently made mandatory.

Patient and public involvement

People with experience in caring for or teaching children with CAs contributed to the development of the survey. These were (a) three parents of children with CAs who also run patient organisations/charities relevant to their child's condition (Down syndrome, spina bifida, metachromatic leukodystrophy), (b) a clinical geneticist who works closely with a number of parent organisations and (c) a teacher of children with special educational needs and disabilities. Each individual commented on an early draft of the survey, including the overall content of the survey and the wording of questions and response options. This feedback was reviewed by the research team and relevant modifications were made to the draft survey to address it.

Findings from the study will be shared with members of the public, parents and carers, healthcare professionals and relevant stakeholders via scientific publications, lay reports, social media and conferences.

Data analysis

Descriptive statistics were conducted using Stata V.17.0 software.³⁴ Data were checked to ensure that answers were consistent (eg, identifying if a mother replying that she is 20-25 years old is retired). Outcomes scored on 4-point Likert scales were dichotomised (very much/ satisfied vs other responses) and outcomes scored on a 5-point Likert scale were collapsed into three categories by merging the two lowest response options (much worse and somewhat worse) and the two highest response options (much better and somewhat better). Data were modelled using multivariate logistic regressions and ordinal logistic regressions, which included the child's anomaly type, parent's country of residence and age and education level. The impact of country and anomaly type on outcomes was explored, choosing the largest categories as the comparator groups (Poland and CHD). For age and education, categorical data were collected. For the analysis, each variable was recoded into three groups: age (<30 years; 31–40 years, >40 years), education (formal education until 16 or 18 years/technical training; university degree; postgraduate degree). Age and education were included in our regression models as ordinal variables. To control for multiple comparisons, the alpha level was adjusted to p<0.01 for all analyses. It was unlikely that data were missing at random, so more sophisticated multiple imputation techniques were not adopted.

We aimed to recruit 80 participants per country which would have resulted in a power of 80% to determine that a country with 20% of participants replying category 4 (very much/satisfied) was statistically significantly different at the 95% level of significance from a country with 40% of participants replying category 4. Owing to delays in obtaining ethics approvals, this target was not met within the timescales for some countries. Data were presented by country if these were available for at least 50 participants. Where there were <50 participants, data were combined into an 'other European country' group (termed, henceforth, as Other EU), which included participants from a heterogeneous group of countries. Due to similarities in survey responses, geographical location and language, data for Belgium (n=46) and the Netherlands (n=28) were combined into a single group. For CAs, data were categorised according to the four anomalies, and a separate category was created for children with Down syndrome and a CHD, a common comorbidity.³⁵ There were too few participants to create meaningful categories for children who had other combinations of the four anomalies (n=15), and these were excluded from the analysis.

Given that a multimodal online recruitment strategy was used, it was not possible to estimate how many potential participants the survey reached in order to calculate response rates.³⁶ We report submission rates (number of participants who started the survey/number who completed




Figure 1 Proportion* of participants reporting 'cancelled or postponed' routine appointments, planned tests or procedures, and planned surgeries with 95% Cls, by country. *Adjusted by congenital anomaly type, parental age and education level.

and submitted the survey).³⁷ For those who submitted their survey, we report item-level response rates (proportion of participants completing each item)³⁸.

RESULTS

Participant characteristics

1298 parents across Europe accessed the survey, of whom 1109 (85%) submitted their responses. The submission rate ranged from 78% in Italy to 92% in Germany and Belgium. A further 123 (9.5%) submitted forms were not included in the analysis as country data were missing (n=80), CA data were missing (n=24), participants were from non-European countries (n=4) or participants specified different combinations of the four anomaly types (n=15). Item-level response rates were above 98% across all outcome variables.

Participants lived in Poland (n=476), the UK (n=120), Germany (n=97), Belgium/Netherlands (n=74), Croatia (n=68), Italy (n=59). The Other EU group (n=92) comprised participants from Denmark (n=39), Portugal (n=23), Spain (n=16), Ireland (n=5), Bulgaria (n=2), Albania (n=1), Cyprus (n=1), Lithuania (n=1), Norway (n=1), Romania (n=1), Sweden (n=1), Ukraine (n=1). Most respondents were mothers (92%), aged 31–40 years (71%) and in full-time or part-time employment (59%) (table 1). In terms of education, 40% of participants had received formal education up to 16–18 years or technical training, 49% had a university degree and 11% a postgraduate degree. Few participants had lived in their country of residence for <10 years (6%).

Child characteristics

The largest CA group was CHD (n=327; 33%). Other children were diagnosed with Down syndrome (n=262; 26%), a cleft lip (n=230; 23%), spina bifida (n=112; 11%) and Down syndrome with a CHD (n=55; 6%). In terms of comorbidities, 25% of children had another CA and 43% had another health condition. The most common age category was 1–3 years (35%) and there was a slightly higher proportion of male children (56%). Just over a third of children attended school (36%), whereas 62% were not yet of school age, and 2% were either home-schooled or unable to be schooled due to their health status.

Provision of healthcare across countries Cancelled or postponed appointments

Cancellations or postponements of routine appointments were reported by 68% (623/920) of the whole sample, by 53% (427/803) for planned tests or procedures and by 26% (121/609) for planned surgeries. The UK and Poland had the largest proportions of parents reporting cancelled or postponed appointments for each category (figure 1). For routine appointments and planned tests/procedures, proportions were significantly lower in Germany, Croatia, Belgium/Netherlands and the Other EU group compared with Poland (table 2). For planned surgeries, all countries except the UK had a significantly lower proportion of cancelled or postponed appointments than Poland (full regression findings are available in online supplemental file 1).

| Table 2 Proportion of participants reporting 'cancelled or postponed' routine appointments, planned tests of | or procedures, and |
|--|--------------------|
| planned surgeries, by country | |

| | Routine appo (N*=920) | Routine appointments N*=920) Planned tests or procedures (N*=803) | | r procedures (N*=803) | Planned surg (N*=609) | eries |
|---------------------|--------------------------|---|---------------|-----------------------|--------------------------|---------------|
| | Unadjusted | Adjusted† | Unadjusted | Adjusted† | Unadjusted | Adjusted† |
| Country | % (95% Cl) | % (95% CI) | % (95% Cl) | % (95% CI) | % (95% Cl) | % (95% CI) |
| Poland | 79 (75 to 83) | 79 (75 to 83) | 66 (61 to 70) | 65 (60 to 70) | 37 (31 to 43) | 35 (29 to 41) |
| UK | 88 (82 to 94) | 86 (80 to 93) | 67 (58 to 76) | 67 (57 to 76) | 31 (20 to 41) | 33 (22 to 44) |
| Germany | 29 (19 to 38) | 31 (21 to 42) | 16 (8 to 24) | 18 (9 to 27) | 7 (1 to 14) | 8 (1 to 15) |
| Croatia | 46 (34 to 58) | 44 (32 to 56) | 36 (23 to 49) | 36 (23 to 49) | 14 (3 to 24) | 13 (3 to 24) |
| Italy | 69 (57 to 81) | 70 (58 to 82) | 52 (38 to 66) | 54 (40 to 68) | 9 (1 to 18) | 11 (0 to 20) |
| Belgium/Netherlands | 34 (23 to 46) | 39 (27 to 51) | 20 (9 to 31) | 23 (11 to 34) | 17 (7 to 27) | 16 (6 to 25) |
| Other EU | 56 (46 to 67) | 57 (47 to 67) | 43 (32 to 53) | 43 (32 to 53) | 12 (4 to 19) | 12 (4 to 20) |

*Total number of participants excluding 'not applicable' responses. Missing data: routine appointments (n=9), planned tests or procedures (n=8), planned surgeries (n=5).

†Adjusted by congenital anomaly type, parental age, and education level.

Virtual appointments (by telephone or online)

Overall, 61% (544/891) of participants reported that their child's face-to-face appointments had been rescheduled as virtual appointments. This proportion was highest in the UK (87%), significantly higher than in Poland (71%). In all other countries, this proportion was significantly lower than Poland (table 3).

Overall, 29% (159/541) of participants reported their child's virtual appointments as being of 'poor' quality overall. This proportion was highest in Poland (37%) and significantly lower in the UK (21%), Belgium/Netherlands (5%) and Germany (0%) (table 3). There was a significant impact of education level on ratings, whereby more highly educated participants were less likely to rate the overall quality of their virtual appointments as 'poor' (OR =0.55, 95% CI 0.41 to 0.77; p=0.000).

Access to medication

Overall, 26% (182/705) of participants reported some problems accessing medication for their child during the pandemic. This proportion was highest in the UK (42%) and Poland (34%) (table 3). Italy (14%), the Other EU group (8%), Germany (7%) and Croatia (4%) all had significantly fewer participants reporting problems compared with Poland (table 3).

Impact on the child's health and well-being across countries

Overall, 30% (221/749) of participants reported that changes to their child's treatment during the pandemic had moderately to severely compromised their child's health. This figure was significantly higher in Poland (43%) compared with the UK (28%), the Other EU group

| prezienie deeeeenig n | | | | | | |
|--|--|--|--|--|--|--|
| | Appointments as virtual (N*= | | Virtual appoint 'poor' (N*=552) | | Problems acce medication (N* | • |
| | Unadjusted | Adjusted† | Unadjusted | Adjusted† | Unadjusted | Adjusted† |
| Country | % (95% CI) | % (95% Cl) | % (95% Cl) | % (95% CI) | % (95% CI) | % (95% CI) |
| Poland | 72 (68 to 76) | 71 (67 to 75) | 37 (32 to 42) | 37 (32 to 43) | 34 (29 to 39) | 34 (29 to 39) |
| UK | 87 (81 to 93) | 87 (81 to 93) | 21 (13 to 29) | 21 (13 to 29) | 43 (33 to 54) | 42 (32 to 52) |
| Germany | 24 (15 to 33) | 25 (16 to 35) | 0 (0 to 17) | 0 (0 to 17) | 6 (1 to 12) | 7 (1 to 14) |
| Croatia | 46 (33 to 59) | 46 (33 to 58) | 15 (2 to 29) | 17 (2 to 31) | 5 (0 to 11) | 4 (0 to 10) |
| Italy | 34 (21 to 47) | 37 (23 to 50) | 29 (8 to 51) | 27 (7 to 48) | 14 (3 to 25) | 14 (3 to 25) |
| Belgium/Netherlands | 28 (17 to 40) | 34 (22 to 46) | 6 (0 to 18) | 5 (0 to 15) | 19 (8 to 29) | 19 (8 to 29) |
| Other EU | 50 (40 to 60) | 52 (42 to 62) | 23 (10 to 35) | 22 (10 to 34) | 9 (2 to 16) | 8 (2 to 14) |
| Germany Croatia Italy Belgium/Netherlands | 24 (15 to 33) 46 (33 to 59) 34 (21 to 47) 28 (17 to 40) | 25 (16 to 35) 46 (33 to 58) 37 (23 to 50) 34 (22 to 46) | 0 (0 to 17) 15 (2 to 29) 29 (8 to 51) 6 (0 to 18) | 0 (0 to 17) 17 (2 to 31) 27 (7 to 48) 5 (0 to 15) | 6 (1 to 12) 5 (0 to 11) 14 (3 to 25) 19 (8 to 29) | 7 (1 to 14) 4 (0 to 10) 14 (3 to 25) 19 (8 to 29) |

Table 3 Proportion of participants reporting appointments rescheduled as virtual, virtual appointments rated as 'poor', and problems accessing medication, by country

*Total number of participants excluding 'not applicable' responses. Missing data: appointments rescheduled as virtual (n=8), virtual appointments rated as 'poor' (n=11), problems accessing medication (n=8). †Adjusted by congenital anomaly type, parental age and education level.




Figure 2 Proportion* of participants reporting that their child's health had been 'moderately to severely' compromised following changes to their child's treatment with 95% Cls, by country. *Adjusted by congenital anomaly type, parental age, and education level.

(20%), Croatia (15%), Italy (12%), Germany (12%) and Belgium/Netherlands (7%) (figure 2).

The majority of participants rated their child's physical health (68%; 634/927) and emotional well-being (56%; 515/927) as being 'about the same' as it was prior to the pandemic. Overall, there was a greater proportion of participants who rated their child's emotional well-being as 'worse' (35%; 319/927) compared with 'worse' ratings for physical health (17%; 162/927).

There was a significant impact of country on ratings for physical health, with all countries less likely to rate their child's physical health as 'worse' than before the pandemic compared with Poland (figure 3). Ratings for the impact of COVID-19 on emotional well-being were similar across countries.

Support for parents across countries

Overall, 23% (220/957) of participants reported that they would have liked more support during the pandemic 'very much'. This proportion was highest in Poland (30%) and significantly lower in Croatia (14%), Belgium/Netherlands (9%) and the other EU group (11%) (figure 4). In terms of the source of support, satisfaction ratings were lowest for support from medical sources and highest for people that participants had close relationships with, such as their partner (table 4).

Medical sources

The UK and Poland had the lowest proportion of 'very satisfied' ratings for general practitioners (GPs), 25% and 26%, respectively (table 4). Compared with Poland,

ratings were significantly higher in Germany (85%) and the other EU group (45%). Italy and Poland had the lowest 'very satisfied' ratings for specialist doctors/nurses, 31% and 32%, respectively. Compared with Poland, ratings were significantly higher in Germany (84%) and the other EU group (45%) (table 4).

Organisations

The highest proportion of 'very satisfied' ratings for patient organisations was for parents in Germany (59%) and Poland (56%) (table 4). Compared with Poland, these satisfaction ratings were significantly lower in the UK (38%) and Belgium/Netherlands (14%). The UK had the highest proportion of participants who were 'very satisfied' with support from their child's school (47%), however, there were no significant countryrelated effects.

Close relationships

Poland had the highest proportion of 'very satisfied' ratings for support from parents of other children with the same health condition (66%), significantly higher than the UK (51%) and Belgium/Netherlands (33%) (table 4). There were no significant differences in satisfaction ratings for support from 'partner' or 'friends/family' across countries.

Outcomes across CA types

There were few differences across CA types, with significant differences only found for items relating to the provision of healthcare. In summary, parents




Figure 3 Proportion* of participants reporting that their child's physical health was 'worse', 'about the same' or 'better' than it was prior to the pandemic with 95% CIs, by country. *Adjusted by congenital anomaly type, parental age, and education level.

of children with CHD (43%) reported a significantly lower proportion of 'cancelled or postponed' tests/ procedures compared with parents of children with spina bifida (65%) and Down syndrome (alone) (62%) (table 5). The CHD group also reported significantly fewer rescheduled appointments (49%) compared with the Down syndrome with CHD (80%), Down syndrome (72%) and spina bifida (70%) groups (table 5). A lower proportion of parents of children with a cleft lip (17%) reported problems accessing medication compared with the CHD group (34%) (table 5).




Figure 4 Proportion* of participants reporting they would have liked more support during the pandemic 'very much' with 95% Cls, by country. *Adjusted by congenital anomaly type, parental age, and education level.

പ്പ

Table 4 Proportion* of participants reporting that they were 'very satisfied' with the support they received from each source, by country

| | GP (N†=775) | Specialist doctor/nurse (N†=792) | Partner (N†=868) | Friends/family (N†=883) | Parents of children with same condition (N†=637) | Patient organisations (N†=510) | Schools (N†=369) |
|-------------------------|----------------|--|---------------------|----------------------------|--|--------------------------------------|---------------------|
| Country | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) |
| Poland | 26 (21 to 30) | 34 (27 to 37) | 69 (65 to 74) | 61 (56 to 66) | 66 (61 to 71) | 56 (50 to 62) | 27 (20 to 34) |
| UK | 25 (16 to 34) | 39 (29 to 49) | 79 (71 to 86) | 49 (40 to 58) | 51 (41 to 61 | 38 (27 to 48) | 47 (34 to 60) |
| Germany | 85 (76 to 94) | 84 (76 to 93) | 89 (81 to 97) | 73 (62 to 85) | 60 (42 to 79) | 59 (38 to 80) | 39 (17 to 61) |
| Croatia | 41 (28 to 53) | 46 (34 to 59) | 80 (1 to 90) | 64 (52 to 75) | 64 (51 to 76) | 36 (21 to 51) | 19 (2 to 36) |
| Italy | 44 (29 to 59) | 31 (16 to 45) | 71 (58 to 84) | 47 (32 to 61) | 44 (26 to 61) | 33 (18 to 49) | 42 (27 to 57) |
| Belgium/ Netherlands | 57 (44 to 72) | 59 (46 to 71) | 66 (54 to 77) | 49 (37 to 61) | 33 (17 to 50) | 14 (0 to 27) | 36 (20 to 52) |
| Other EU | 45 (33 to 57) | 45 (34 to 56) | 70 (60 to 79) | 52 (42 to 63) | 56 (43 to 68) | 38 (26 to 51) | 33 (19 to 46) |
| Total | 37 (33 to 40) | 42 (39 to 45) | 72 (70 to 75) | 58 (55 to 61) | 60 (56 to 64) | 46 (42 to 50) | 34 (29 to 38) |

*Adjusted by congenital anomaly type, parental age and education level. Unadjusted proportions are not included in this table.

 \dagger Total number of participants completing the item, excluding 'not applicable' responses. Missing data: GP (n=10), specialist doctor/nurse (n=16), partner (n=11), friends/family (n=14), parents of children with same condition (n=17), patient organisations (n=18), schools (n=35). GP, general practitioner.

DISCUSSION Main findings

This study provides a snapshot of the healthcare experiences of children with CAs and their caregivers' experiences of support across Europe, 1 year into the COVID-19 pandemic. Overall, many participants reported disruptions to their child's routine care, which appeared to have an impact on the health of some children. Compared with non-medical organisations and parents' close relationships, parents were least satisfied with support from GPs and specialist doctors/nurses, which was particularly poor in Poland and the UK. There were also regional differences in the proportions of parents reporting disruptions to healthcare, which again appeared most severe in Poland and the UK. Few differences were found in outcomes according to CA type, suggesting that the geographical location of participants had more of an influence on healthcare experiences than the child's specific health condition.

While acknowledging that a range of factors may underpin differences across countries (such as reductions in hospital visits to minimise infections), a possible hypothesis is that these are indicative of existing vulnerabilities within local healthcare systems, with lower resourced systems being less able to meet the needs of patients during the pandemic. In relation to the healthcare workforce, figures from the Organisation for Economic Co-operation and Development in 2018 indicate that Poland had the lowest numbers of practising doctors per head in Europe (2.3/1000), closely followed by the UK (2.8/1000).³⁹ In contrast, Germany had one of the highest numbers per head in Europe (4.4/1000).³⁹ Among European countries, Poland, Italy and the UK also had below average numbers of practicing nurses per head, a factor associated with patient satisfaction with care,⁴⁰ which ranged from 5.1 to $7.8/1000.^{39}$ In comparison, the Netherlands, Belgium and Germany all had above average figures, 11.1, 11.2 and 13.1/1000, respectively. A larger number of healthcare workers is likely to have helped with increased demand during the pandemic and helped mitigate the consequences of staff sickness.³⁹ Other factors that may account for regional differences include our method of recruitment and the severity of local restrictions. Participants were recruited with a consistent strategy across countries; however, some had a greater number of organsations who advertised the study and some were able to request that these organisations advertise the survey more frequently (eg, in Poland). Recruitment periods also differed, ranging from 18 weeks in the UK and Poland to only 6.5 weeks in Italy (table 1). As people are more likely to respond to surveys which are highly salient to their experiences,⁴¹ one might expect parents experiencing more challenges during the pandemic to have been more likely to respond. However, our survey was a general survey about parents' information and support needs, with only one subsection relating to the pandemic, so this is unlikely. It is difficult to estimate the extent to which variations in the depth and duration of COVID-19 containment strategies might have influenced cross-country variations in outcomes. Containment strategies varied both regionally, within each country, and internationally, during the survey recall period (January 2020-July 2021). In addition, all countries experienced a period of full lockdown during this timeframe, making these other variations less pertinent.

| Congenital nomalyUnadjustedUnadjustedUnadjustedUnadjustedAdjustedfNeglostedfUnadjustedAdjustedf $nomaly$ $\%(95\% Cl)$ $\%($ | | Planned tests or procedures (N*=803) | r procedures | Appointments rescheduled as virtual (N*=891) | escheduled as | Virtual appointments rated as 'poor' (N*=552) | nents rated as | Problems acce: (N*=713) | Problems accessing medication (N*=713) |
|---|---------------------------|--------------------------------------|---------------|--|---------------|---|----------------|----------------------------|--|
| V %(95% Cl) %(71 (10 2) %(71 | Congenital | Unadjusted | Adjusted† | Unadjusted | Adjusted† | Unadjusted | Adjusted† | Unadjusted | Adjusted† |
| 42 (36 to 47) 43 (37 to 49) 46 (41 to 52) 49 (44 to 55) 36 (29 to 44) 36 (28 to 44) 31 (25 to 36) 48 (41 to 55) 51 (44 to 58) 52 (45 to 58) 56 (49 to 62) 33 (24 to 42) 29 (21 to 38) 16 (9 to 22) fida 64 (54 to 73) 65 (56 to 73) 66 (58 to 75) 70 (62 to 77) 30 (19 to 40) 27 (17 to 37) 30 (21 to 39) indrome 67 (61 to 73) 62 (55 to 68) 76 (71 to 81) 72 (67 to 78) 28 (21 to 34) 29 (22 to 36) 27 (20 to 33) indrome 60 (47 to 74) 55 (40 to 68) 83 (73 to 93) 80 (69 to 91) 33 (18 to 47) 28 (13 to 42) 20 (8 to 31) | anomaly | %(95% CI) | %(95% CI) | %(95% CI) | % (95% CI) | %(95% CI) | %(95% CI) | %(95% CI) | %(95% CI) |
| 48 (41 to 55) 51 (44 to 58) 52 (45 to 58) 56 (49 to 62) 33 (24 to 42) 29 (21 to 38) 16 (9 to 22) fida 64 (54 to 73) 65 (56 to 73) 66 (58 to 75) 70 (62 to 77) 30 (19 to 40) 27 (17 to 37) 30 (21 to 39) indrome 67 (61 to 73) 62 (55 to 68) 76 (71 to 81) 72 (67 to 78) 28 (21 to 34) 29 (22 to 36) 27 (20 to 33) indrome 60 (47 to 74) 55 (40 to 68) 83 (73 to 93) 80 (69 to 91) 33 (18 to 47) 28 (13 to 42) 20 (8 to 31) | CHD | 42 (36 to 47) | 43 (37 to 49) | 46 (41 to 52) | 49 (44 to 55) | 36 (29 to 44) | 36 (28 to 44) | 31 (25 to 36) | 34 (21 to 40) |
| 64 (54 to 73) 65 (56 to 73) 66 (58 to 75) 70 (62 to 77) 30 (19 to 40) 27 (17 to 37) 30 (21 to 39) ome 67 (61 to 73) 62 (55 to 68) 76 (71 to 81) 72 (67 to 78) 28 (21 to 34) 29 (22 to 36) 27 (20 to 33) ome 60 (47 to 74) 55 (40 to 68) 83 (73 to 93) 80 (69 to 91) 33 (18 to 47) 28 (13 to 42) 20 (8 to 31) | Cleft lip | 48 (41 to 55) | 51 (44 to 58) | 52 (45 to 58) | 56 (49 to 62) | 33 (24 to 42) | 29 (21 to 38) | 16 (9 to 22) | 17 (10 to 23) |
| drome 67 (61 to 73) 62 (55 to 68) 76 (71 to 81) 72 (67 to 78) 28 (21 to 34) 29 (22 to 36) 27 (20 to 33) drome 60 (47 to 74) 55 (40 to 68) 83 (73 to 93) 80 (69 to 91) 33 (18 to 47) 28 (13 to 42) 20 (8 to 31) | Spina bifida | 64 (54 to 73) | 65 (56 to 73) | 66 (58 to 75) | 70 (62 to 77) | 30 (19 to 40) | 27 (17 to 37) | 30 (21 to 39) | 28(19 to 36) |
| drome 60 (47 to 74) 55 (40 to 68) 83 (73 to 93) 80 (69 to 91) 33 (18 to 47) 28 (13 to 42) 20 (8 to 31) | Down syndrome | | 62 (55 to 68) | 76 (71 to 81) | 72 (67 to 78) | 28 (21 to 34) | 29 (22 to 36) | 27 (20 to 33) | 24 (18 to 30) |
| | Down syndrome with CHD | | 55 (40 to 68) | 83 (73 to 93) | 80 (69 to 91) | 33 (18 to 47) | 28 (13 to 42) | 20 (8 to 31) | 17 (6 to 27) |

The use of virtual healthcare appointments during the pandemic meant parental concerns about cancellations could be addressed, while limiting their exposure to SARS-CoV-2.¹⁹ Around 60% of our sample reported that they had a face-to-face appointment rescheduled as virtual. This was higher than other in other studies conducted with paediatric patients, which found that $11\%^{18}$ and $20\%^{23}$ of participants reporting rescheduled appointments. However, these studies were conducted during the first wave of the pandemic (April-May 2020), a year before our survey was delivered, so this rise is not unexpected. The quality of virtual appointments was rated as 'fair-excellent' by two-thirds of our sample, whereas one-third rated them as 'poor'. This is in line with findings from a similar survey, which found that 68% of CHD parents and patients described their virtual appointments as 'adequate'.²³ In contrast, other studies conducted within specialist paediatric centres found higher satisfaction ratings,^{19 42} such as 87% mean satisfaction ratings for virtual paediatric appointments.43 This increase, however, may be due to a slight social-desirability bias as parents were asked to rate satisfaction by staff within the specialist centres, whereas in our survey, the recruiters were not involved in the child's care. Of note is our finding whereby participants with a lower level of education were more likely to rate virtual appointments as poor.

Strengths and limitations

This study surveyed parents and carers of children with different CA types within several countries, including a broad range of experiences. We recruited a large sample of parents and carers overall, and the proportion of each CA type reflects the relative number of live births with each CA in Europe.⁴⁴ Although the survey was shared widely, the use of convenience sampling means that there is a risk of selection bias, and the views and experiences of this sample may not be representative of all parents and carers of children with CAs. The use of social media to recruit participants may have excluded people living with 'digital poverty' and people who do not tend to engage with these types of organisations, whose experiences may differ from this sample. When considering recruitment figures within each country, these were mostly small. The survey was developed with input from parents of children with a CA, however, we were unable to conduct a full pilot of the final version. Great care was taken to avoid leading questions, ambiguity or complex language; however, it is possible that there may have been some issues with the wording or content of survey items.

Implications and future research

CA, congenital anomaly; CHD, congenital heart defects.

Our survey findings are important and provide useful insights into the provision of care for children with CAs across Europe during the first year of the pandemic. Findings highlight potential weaknesses of healthcare systems in some countries and suggest that long-term systemic action is required to improve patient experiences and outcomes. The situation appears particularly problematic in the UK and Poland, which may benefit from increased resources to provide for this vulnerable group of patients. Patient organisations and charities provide an invaluable source of knowledge and support to parents of children with CAs, and these should be supported, especially in countries where medical capacity to meet patients' needs may be stretched.

As with many other patient groups, it is clear that the COVID-19 pandemic has had an impact on the experiences of children living with a serious health condition and their families.^{20 22 45} This particular survey suggests disruptions to care for children, with potential impacts on the child's health and well-being. Considering the limitations of this study, it will be important to further investigate the impact of the COVID-19 pandemic on the delivery of paediatric services across Europe using population-based data. With the proliferation of telemedicine to deliver care during the pandemic,⁴³ exploring the reasons why these virtual strategies were lacking for some parents (particularly those with a lower level of education) is important to ensure optimal parental satisfaction with future care and support from medical professionals.

Conclusion

The COVID-19 pandemic continues to put pressure on healthcare systems worldwide. Our survey findings highlight disruptions to the delivery of care across Europe, particularly in the UK and Poland, which raises questions about the ability of the healthcare systems within these countries to meet the needs of children with CAs and their families, and a need for increased resources.

Author affiliations

¹Chair and Department of Medical Genetics, University of Medical Sciences, Poznan, Poland

²Population Health Research Institute, St George's University of London, London, UK ³Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK

⁴Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia

⁵Rare Diseases Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain

⁶Provincial Institute for Hygiene, Antwerpen, Belgium

⁷Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark

⁸Department of Epidemiology, National Health Institute Doutor Ricardo Jorge, Lisboa, Portugal

⁹Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands

¹⁰Department of Epidemiology, National Institute of Health, Lisbon, Portugal ¹¹IMER Registry (Emilia Romagna Registry of Birth Defects), University of Ferrara and Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy

¹²Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University, Magdeburg, Germany

¹³Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, Pisa, Italy

¹⁴Population Health Research Institute, St George's, University of London, London, UK

Twitter Elena Marcus @_elenamarcus

Acknowledgements The authors are hugely grateful to all the parents and carers who took part in the study. We thank the following people for their support in developing the survey and its dissemination in Poland: Dominika Madaj-Solberg

(Spina Foundation, Katowice, Poland), Tomek i Kasia Grybek (Borys the Hero Foundation, Gdańsk, Poland), Halina Grzymisławska-Słowińska (Fundacia TAK dla Samodzielności, Poznań, Poland), Anna Latos (Bydgoszcz, Poland), Professor Jolanta Wierzba (Med.Univ. Gdańsk, Poland), Professor Robert Śmigiel (Med. Univ. Wrocław, Poland), Professor Olga Haus (Coll.Med. UMK, Bydgoszcz, Poland), and Dorota Trześniewska (Poznań, Poland). We thank the following people and organisations for advertising the survey across Europe: The Cleft Lip and Palate Association, The Children's Heart Federation, International Federation for Spina Bifida and Hydrocephalus, Children's Heartbeat Trust, Down's Syndrome Association, and Down Syndrome International, Dr Nadia Assanta (Fondazione Toscana Gabriele Monasterio). Dr Giada Cavazzuti (Associazione 'Un cuore, un mondo'). Dr Elisabetta Lapi, Dr Antonella Falugiani (Associazione 'Trisomia 21 Onlus'), Dr Alessandro Giacomina, Dr Marina Rossi (AOU Pisana), Jürgen Wolters (Arbeitsgemeinschaft Spina Bifida und Hydrocephalus, ASBH), Dr Annett Lambrecht (Department of Pediatric Cardiology, University Hospital Magdeburg), Dr Christian Zahl (Department of Oral and Maxillofacial Surgery, University Hospital Magdeburg), Hjerteforeningens børneklub (Kid's Heart Association Club), Rygmarvsbrokforeningen (Spina Bifida and Hydrocephalus Association), Downs syndrom Danmark (Danish Down Syndrome), Landsforeningen Læbe- Ganespalte (Cleft Lip and Palate Association), Pais21 (Down Portugal/ Down Syndrom Parents Association Pais 21), Associação Spina Bifida e Hidrocefalia de Portugal (Spina Bifida and Hidrocephalus Portugal Association), Associação Coração Feliz (Happy Heart Association), Associação Portuguesa dos Amigos das Crianças Portadoras de Fendas Lábio-Palatinas (Portugese Association of Children with Lip-Palatine Clefts), The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Universitair Ziekenhuis Antwerpen (University Hospital of Antwerp), Vereniging voor Aangeboren Gelaatsafwijkingen (Association for Congenital Facial Defects), Dr Annick Laridon -Het Centrum voor Ontwikkelingsstoornissen (Centre for Developmental Disorders), Mario Sel - Spina Bifida Hydrocephalus Belgium, Hrvatski savez za rijetke bolesti (Rare Diseases Croatia), Veliko srce malom srcu (A Big Heart For Little Heart), Hrvatska zajednica za Down sindrom (Croatian Down Syndrome Association), Udruga roditelja djece s rascjepom usne i/ili nepca OSMIJEH (Association of Children With Cleft Lip With/Without Cleft Palate). Udruga Aurora- Udruga roditelia i djece sa spinom bifidom (Aurora Association-Association of Parents and Children with Spina Bifida), Patientenvereniging Aangeboren Hartaandoeningen (Congenital Heart Disease Association), De 'Stichting Downsyndroom' (Down Syndrome Association). We are very grateful to Esben Garne Holm and Juan Rico for supporting the translation of the survey.

Contributors AL-B conceptualised the study. AL-B, EM, JKM, and JR contributed to the study design and survey development. EM led the survey development, translation, and recruitment of participants. EM and JKM conducted the data analysis. AL-B, JKM, and JR critically revised the manuscript. AJ-D, IB, CC-C, EDH, EG, EM, LG, AJS, LRL, CMD, CNP, AJN, AN, LO, LP-R, AP and AR oversaw the translation of the survey and recruited participants. EM drafted the manuscript. All authors contributed to, read and approved the final manuscript. JKM acts as a guarantor for the manuscript.

Funding This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 733001. Start date: 1 January 2017. Duration: 5 years and 5 months. The views presented here are those of the authors only, and the European Commission is not responsible for any use that may be made of the information presented here.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval Ethics approval for the study was granted by the St George's (University of London). Research Ethics Committee on 18 December 2020 (reference number: 2020.0311). In Poland, ethics approval was granted on 10 December 2020 by the Bioethics Committee at the Poznań University of Medical Sciences (reference number: 882/20). In Croatia, ethics approval was granted on 10 December 2020 by the Ethics Committee of the Children's Hospital Zagreb (Protocol No: 02-23/43-1-20 Zagreb). In Spain, ethics approval was granted on 21 December 2020 by the Clinical Investigation Ethics Committee of the "Dirección General de Salud Pública y Centro Superior de Investigación en Salud Pública" (reference number: 20201221/05). In Belgium, ethics approval was granted on 1 March 2021 by the Ethics Committee of the University Hospital of Antwerp (reference: 21/06/084). In Portugal, ethics approval was granted on 16 March by the Ethics Committee of the National Institute of Health Doutor Ricardo Jorge (CES-INSA). In

Germany, ethics approval was granted on 15 April 2021 by the Medical Faculty of the Otto-von-Guericke-University Magdeburg Research Ethics Committee (reference number: 44/21). In Italy, ethics approval was granted on 14 June 2021 by the Research Ethics and Integrity Committee of the National Research Council Institute of Clinical Physiology in Pisa (CNR-INF) (protocol number 0065527/2019). No local ethics approvals were required in Denmark (Lillebaelt Hospital—University Hospital of Southern Denmark) or the Netherlands (University Medical Center Groningen).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The datasets analysed during the current study are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Elena Marcus http://orcid.org/0000-0003-0900-8976 Clara Cavero- Carbonell http://orcid.org/0000-0002-4858-6456 Ester Garne http://orcid.org/0000-0003-0430-2594 Lucía Páramo-Rodríguez http://orcid.org/0000-0002-2952-564X Anke Rissmann http://orcid.org/0000-0002-9437-2790 Joan K Morris http://orcid.org/0000-0002-7164-612X

REFERENCES

- Smolić Šime, Čipin I, Međimurec P. Access to healthcare for people aged 50+ in Europe during the COVID-19 outbreak. *Eur J Ageing* 2021:1–17.
- 2 Cena L, Rota M, Calza S, *et al.* Estimating the impact of the COVID-19 pandemic on maternal and perinatal health care services in Italy: results of a self-administered survey. *Front Public Health* 2021;9:701638.
- 3 van Veenendaal NR, Deierl A, Bacchini F, et al. Supporting parents as essential care partners in neonatal units during the SARS-CoV-2 pandemic. Acta Paediatr 2021;110:2008–22.
- 4 Gardner T, Fraser C. *Elective care: how has COVID-19 affected the waiting list*? London: The Health Foundation, 2021. https://bit.ly/ 3EKqvRL
- 5 Chiumento A, Baines P, Redhead C, *et al.* Which ethical values underpin England's National Health Service reset of paediatric and maternity services following COVID-19: a rapid review. *BMJ Open* 2021;11:e049214.
- 6 Colvin L, Bower C. A retrospective population-based study of childhood hospital admissions with record linkage to a birth defects registry. *BMC Pediatr* 2009;9:32.
- 7 Rosano A, Botto LD, Botting B, et al. Infant mortality and congenital anomalies from 1950 to 1994: an international perspective. J Epidemiol Community Health 2000;54:660–6.
- 8 Department of Health. National framework for children and young peoples continuing care. London: Department of Health, 2016.
- 9 Razzaghi H, Dawson A, Grosse SD, et al. Factors associated with high hospital resource use in a population-based study of children with orofacial clefts. *Birth Defects Res A Clin Mol Teratol* 2015;103:127–43.
- 10 Fitzgerald P, Leonard H, Pikora TJ, *et al*. Hospital admissions in children with down syndrome: experience of a population-based cohort followed from birth. *PLoS One* 2013;8:e70401.
- 11 Bishop CF, Small N, Parslow R, et al. Healthcare use for children with complex needs: using routine health data linked to a multiethnic, ongoing birth cohort. BMJ Open 2018;8:e018419.
- 12 Alanazi AFR, Naser AY, Pakan P, et al. Trends of hospital admissions due to congenital anomalies in England and Wales between 1999

and 2019: an ecological study. Int J Environ Res Public Health 2021;18:11808.

- 13 Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020;109:1088–95.
- 14 Malle L, Gao C, Hur C, et al. Individuals with down syndrome hospitalized with COVID-19 have more severe disease. *Genet Med* 2021;23:576–80.
- 15 Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in down syndrome: results from a cohort study of 8 million adults. Ann Intern Med 2021;174:572–6.
- 16 Malviya A, Yadav R. COVID -19 pandemic and paediatric population with special reference to congenital heart disease. *Indian Heart J* 2020;72:141–4.
- 17 Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of COVID-19 disease in pediatric oncology patients: the New York-New Jersey regional experience. Pediatr Blood Cancer 2021;68:e28843.
- 18 Poppe M, Aguiar B, Sousa R, *et al.* The impact of the COVID-19 pandemic on children's health in Portugal: the parental perspective. *Acta Med Port* 2021;34:355–61.
- 19 Darr A, Senior A, Argyriou K, et al. The impact of the coronavirus (COVID-19) pandemic on elective paediatric otolaryngology outpatient services - An analysis of virtual outpatient clinics in a tertiary referral centre using the modified paediatric otolaryngology telemedicine satisfaction survey (POTSS). Int J Pediatr Otorhinolaryngol 2020;138:110383.
- 20 Wray J, Pagel C, Chester AH, *et al.* What was the impact of the first wave of COVID-19 on the delivery of care to children and adults with congenital heart disease? A qualitative study using online forums. *BMJ Open* 2021;11:e049006.
- 21 The Cleft Lip and Palate Association. Summer survey 2020: the results, 2020. Available: https://www.clapa.com/news-item/summersurvey-2020-the-results/ [Accessed 2 Nov 2021].
- 22 Marino LV, Wagland R, Culliford DJ, et al. No official help is available - experience of parents and children with congenital heart disease during COVID-19. World J Pediatr Congenit Heart Surg 2021;12:500–7.
- 23 Cousino MK, Pasquali SK, Romano JC, et al. Impact of the COVID-19 pandemic on CHD care and emotional wellbeing. Cardiol Young 2021;31:822–8.
- 24 Stewart A, Smith CH, Eaton S, et al. COVID-19 pandemic experiences of parents caring for children with oesophageal atresia/tracheo-oesophageal fistula. BMJ Paediatr Open 2021;5:e001077.
- 25 Mongru R, Rose DF, Costelloe C, et al. Retrospective analysis of North West London healthcare utilisation by children during the COVID-19 pandemic. BMJ Paediatr Open 2022;6:e001363.
- 26 Kruizinga MD, Peeters D, van Veen M, *et al.* The impact of lockdown on pediatric ED visits and hospital admissions during the COVID19 pandemic: a multicenter analysis and review of the literature. *Eur J Pediatr* 2021;180:2271–9.
- 27 Nicholson E, McDonnell T, Conlon C, et al. Parental hesitancy and concerns around accessing paediatric unscheduled healthcare during COVID-19: a cross-sectional survey. Int J Environ Res Public Health 2020;17:11.
- 28 Liguoro I, Pilotto C, Vergine M, et al. The impact of COVID-19 on a tertiary care pediatric emergency department. *Eur J Pediatr* 2021;180:1497–504.
- 29 Dorfman L, Nassar R, Binjamin Ohana D, et al. Pediatric inflammatory bowel disease and the effect of COVID-19 pandemic on treatment adherence and patients' behavior. *Pediatr Res* 2021;90:637–41.
- 30 Morris JK, Garne E, Loane M, *et al.* EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies. *BMJ Open* 2021;11:e047859.
- 31 Cuschieri S. The STROBE guidelines. Saudi J Anaesth 2019;13:S31–4.
- 32 Kuliś D, Bottomley A, Velikova G. *EORTC quality of life group translation procedure*. 4th edn, 2017. https://www.eortc.org/app/ uploads/sites/2/2018/02/translation_manual_2017.pdf
- 33 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
- 34 Stata statistical software: release 17 (College Station, TX: StataCorp LLC, 2021).
- 35 Leirgul E, Fomina T, Brodwall K, et al. Birth prevalence of congenital heart defects in Norway 1994-2009--a nationwide study. Am Heart J 2014;168:956–64.
- 36 McRobert CJ, Hill JC, Smale T, et al. A multi-modal recruitment strategy using social media and internet-mediated methods to recruit

a multidisciplinary, international sample of clinicians to an online research study. *PLoS One* 2018;13:e0200184.

- 37 Liu M, Wronski L. Examining completion rates in web surveys via over 25,000 real-world surveys. Soc Sci Comput Rev 2018;36:116–24.
- 38 Bosnjak M, Tuten TL. Classifying response behaviors in web-based surveys. J Comp Med Commun 2001;6.
- 39 OECD & European Union. Health at a glance: Europe 2020. state of health in the EU cycle. Paris: OECD Publishing, 2020. https://doi.org/ 10.1787/82129230-en
- 40 Aiken LH, Sloane DM, Ball J, et al. Patient satisfaction with hospital care and nurses in England: an observational study. BMJ Open 2018;8:e019189.
- 41 Saliba A, Ostojic P. Personality and participation: who volunteers to participate in studies. *Psychology* 2014;05:230–43.

- 42 Gali K, Joshi S, Hueneke S, *et al.* Barriers, access and management of paediatric epilepsy with telehealth. *J Telemed Telecare* 2022;28:213–23.
- 43 Pooni R, Pageler NM, Sandborg C, et al. Pediatric subspecialty telemedicine use from the patient and provider perspective. *Pediatr Res* 2022;91:241–6.
- 44 European Commission and EUROCAT. Prevalence charts and data on congenital anomalies, 2021. Available: https://eu-rd-platform.jrc. ec.europa.eu/eurocat/eurocat-data/prevalence_en [Accessed 30 Nov 2021].
- 45 Darlington A-SE, Morgan JE, Wagland R, *et al.* COVID-19 and children with cancer: parents' experiences, anxieties and support needs. *Pediatr Blood Cancer* 2021;68:e28790.

SUPPLEMENTARY FILE

(A) SURVEY ITEMS

(1) Parent Demographics

1. Which country do you live in? [drop-down list]

- 2. What type of area do you live in?
 - a. City (population over 500,000)
 - b. Large town (population between 100,000 and 500,000)
 - c. Medium town (population between 20,000 and 100,000)
 - d. Small town (population less than 20,000)
 - e. Suburban village
 - f. Village
 - g. Rural/isolated area (e.g. a farm)
- 3. What is your age?
 - a. Less than 20 years
 - b. 20-25 years
 - c. 26-30 years
 - d. 31-35 years
 - e. 36-40 years
 - f. 41-45 years
 - g. 46-50 years
 - h. More than 50 years
- 4. What is the highest level of education you have completed?
 - a. Primary school
 - b. Secondary school up to 16 years
 - c. Secondary or further education after 16 years
 - d. University
 - e. Post-graduate / Doctoral studies
- 5. What is your employment status?
 - a. Employed (full-time), including self-employed
 - b. Employed (part-time), including self-employed
 - c. Full-time homemaker/carer
 - d. Long-term sick/disabled
 - e. Retired
 - f. Student
 - g. Unemployed
 - h. On furlough

6. How long have you lived in your country of residence?

- a. Up to 1 year
- b. Between 1-5 years
- c. Between 6-10 years
- d. More than 10 years
- e. From birth

f. Prefer not to say

7. What is your relationship to the child this survey is about?

- a. Mother (biological)
- b. Mother (adoptive)
- c. Father (biological)
- d. Father (adoptive)
- e. Legal guardian related to the child
- f. Legal guardian unrelated to the child / foster parent
- g. Another family member

8. Is your child being raised with any siblings?

- a. Yes, biological sibling(s)
- b. Yes, adoptive sibling(s)
- c. Yes, biological and adoptive siblings
- d. No [survey skips to next section]

9. Is their sibling/are their siblings older or younger than the child this survey is about?

- a. Older
- b. Younger
- c. Both older and younger
- d. Same age (twin)

(2) Child Demographics and Medical Information

- 1. What age is your child?
 - a. Less than 1 year
 - b. 1-3 years
 - c. 4-6 years
 - d. 7-10 years

2. What is your child's gender?

- a. Male
- b. Female
- c. Other
- d. Prefer not to say

3. Which of the following conditions has your child been diagnosed with? (If your child has <u>more</u> <u>than one</u> of these conditions, please select all that apply)

- a. Cleft lip (with or without cleft palate)
- b. Spina bifida
- c. Congenital heart defect that required surgical intervention
- d. Down's syndrome
- 4. Was your child's [condition] detected prenatally (during pregnancy)?
 - a. Yes [survey moves to question 5]
 - b. No [survey skips to question 6]
 - c. I don't know [survey skips to question 6]

- 5. In which week of pregnancy was your child's [condition] detected?
 - a. Before 13 weeks
 - b. Between 14 and 21 weeks
 - c. At 22 weeks or later
 - d. I'm not sure
- 6. Does your child have any other congenital anomalies (conditions present from birth)?

a. Yes

- Please select all that apply:
 - Brain anomalies
 - Hydrocephalus
 - Eye anomalies
 - Anomalies of face, ear and neck
 - Lung anomalies
 - Abdominal anomalies
 - Renal anomalies
 - Genital anomalies
 - Skeletal anomalies
 - Limb anomalies
 - Chromosomal or genetic abnormality (other than Down's syndrome)
 - Other anomaly
- b. No

7. Does your child have any other health conditions?

a. Yes

- Please select all that apply:
 - Autism or attention disorder
 - Learning disability
 - Epilepsy
 - Cerebral Palsy
 - Asthma
 - Allergy or food intolerance
 - Eczema or other skin disease
 - Recurrent infections
 - Hearing loss
 - Vision problems
 - Celiac disease
 - Diabetes
 - Endocrine disorder
 - Immune disorder
 - Blood disorder
 - Cancer
 - Other
- b. No

(3) Provision of healthcare

1. Has your child had any routine appointments postponed or cancelled?

- a. Yes
- b. No
- c. Not applicable (they have not had any routine appointments in this period)

2. Has your child had any planned surgeries postponed or cancelled?

- a. Yes
- b. No
- c. Not applicable (they have not had any planned surgeries in this period)

3. Has your child had any planned tests or procedure's postponed or cancelled?

- a. Yes
- b. No
- c. Not applicable (they have not had any planned tests or procedures in this period)

4. Has your child had any <u>face-to-face appointments</u> re-scheduled as virtual appointments (e.g. by telephone or online)?

- a. Yes
- b. No
- c. Not applicable (they have not had any appointments in this period)

5. [If yes] Overall, how do you rate the <u>quality</u> of your virtual appointments?

- a. Poor
- b. Fair
- c. Good
- d. Very good

7. Have you had any difficulty accessing medication for your child?

- a. Not at all
- b. A little
- c. Quite a bit
- d. Very much
- e. Not applicable (they do not require medication)

(4) Impact on the child

1. Has your <u>child's health</u> been compromised by any changes to ongoing treatment for their condition (e.g. medication, physical therapy, or surgery)?

- a. Not at all
- b. Slightly
- c. Moderately
- d. Severely
- e. Not applicable (there have been no changes to their ongoing treatment)
- f. Not applicable (they have not had any ongoing treatment)

2. Compared to before COVID-19, how would you rate your child's physical health?

- a. Much worse
- b. Somewhat worse
- c. About the same
- d. Somewhat better
- e. Much better

3. Compared to before COVID-19, how would you rate your child's emotional well-being?

- a. Much worse
- b. Somewhat worse
- c. About the same
- d. Somewhat better
- e. Much better

(5) Support for Parents

1. During the pandemic, to what extent have you <u>felt satisfied</u> with the support you have received from the following people/organisations? (If you <u>have not</u> needed or requested support from a listed source please select N/A)

| | Not at all satisfied | Slightly satisfied | Moderately satisfied | Very satisfied | N/A |
|--|----------------------|--------------------|-------------------------|-------------------|-----|
| General practitioner | | | | | |
| Specialist doctor or specialist nurse | | | | | |
| Partner (or person I am closest to) | | | | | |
| Friends and family | | | | | |
| Parents of children with the same health condition | | | | | |
| Patient/parent organisation | | | | | |
| School | | | | | |

2. Overall, would you have liked more support during the COVID-19 pandemic?

- a. Not at all
- b. A little
- c. Quite a bit
- d. Very much

(B) STROBE CHECKLIST

| STROBE Statement— | -Check | list of items that should be included in reports of cross-sectional | studies |
|------------------------------|------------|--|------------|
| | Item No | Recommendation | Page No |
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1, 3 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 3 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4-5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5, 7 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5-7 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | 7 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 7-8 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7 |
| Bias | 9 | Describe any efforts to address potential sources of bias | n/a |
| Study size | 10 | Explain how the study size was arrived at | 9 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 9 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 9-10 |
| | | (b) Describe any methods used to examine subgroups and interactions | 9-10 |
| | | (c) Explain how missing data were addressed | 9-10 |
| | | (<i>d</i>) If applicable, describe analytical methods taking account of sampling strategy | n/a |
| | | (<u>e</u>) Describe any sensitivity analyses | n/a |

| Results Participants | 13* | (a) Report numbers of individuals at each stage of study—eg | 10 |
|-------------------------|-----|--|------------------------------|
| · | | numbers potentially eligible, examined for eligibility, confirmed | |
| | | eligible, included in the study, completing follow-up, and analysed | |
| | | (b) Give reasons for non-participation at each stage | n/a |
| | | (c) Consider use of a flow diagram | n/a |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 6, 10 |
| | | (b) Indicate number of participants with missing data for each variable of interest | 10 (and Tables 2-5) |
| Outcome data | 15* | Report numbers of outcome events or summary measures | n/a |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder- | 11-14, |
| | | adjusted estimates and their precision (eg, 95% confidence | 16 |
| | | interval). Make clear which confounders were adjusted for and | (Table |
| | | why they were included | 2-5) |
| | | (b) Report category boundaries when continuous variables were categorized | n/a |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | n/a |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | n/a |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 17 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 18-19 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 17-18 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 18 |
| Other information | | | 1 |
| Funding | 22 | Give the source of funding and the role of the funders for the | 21-22 |
| - | | present study and, if applicable, for the original study on which | |
| | | the present article is based | |

*Give information separately for exposed and unexposed groups. **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

(C) LOGISTIC REGRESSION FINDINGS

| Routine Appointments | Odds ratio | Standard error | Z | P> z | [95% conf. | interval] |
|----------------------|------------|-------------------|-------|-------|------------|-----------|
| Country | | | | | | |
| UK | 1.70 | 0.52 | 1.73 | 0.084 | 0.93 | 3.11 |
| Germany | 0.11 | 0.03 | -7.8 | 0.000 | 0.06 | 0.19 |
| Croatia | 0.20 | 0.06 | -5.62 | 0.000 | 0.11 | 0.35 |
| Italy | 0.62 | 0.20 | -1.46 | 0.144 | 0.32 | 1.18 |
| Belgium/Nether | 0.16 | 0.05 | -6.37 | 0.000 | 0.09 | 0.28 |
| Other | 0.34 | 0.09 | -4.21 | 0.000 | 0.20 | 0.56 |
| | | | | | | |
| Age | 1.32 | 0.17 | 2.19 | 0.029 | 1.03 | 1.69 |
| Education | 1.14 | 0.15 | 0.99 | 0.325 | 0.88 | 1.46 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.03 | 0.22 | 0.15 | 0.883 | 0.68 | 1.55 |
| Spina bifida | 1.47 | 0.39 | 1.46 | 0.143 | 0.88 | 2.48 |
| Down syndrome | 1.85 | 0.41 | 2.78 | 0.005 | 1.20 | 2.86 |
| DS + CHD | 2.09 | 0.82 | 1.88 | 0.061 | 0.97 | 4.53 |
| | | | | | | |
| _cons | 1.36 | 0.47 | 0.89 | 0.373 | 0.69 | 2.67 |

 Table 1 Logistic regression model output for cancelled/postponed routine appointments

CHD – congenital heart defect; CA – congenital anomaly.

| | | Standard | | | | |
|----------------|------------|----------|-------|-------|---------------|----------|
| Surgeries | Odds ratio | error | Z | P> z | [95% conf. ir | nterval] |
| Country | | | | | | |
| UK | 0.91 | 0.27 | -0.3 | 0.761 | 0.51 | 1.65 |
| Germany | 0.16 | 0.08 | -3.68 | 0.000 | 0.06 | 0.43 |
| Croatia | 0.27 | 0.14 | -2.6 | 0.009 | 0.10 | 0.73 |
| Italy | 0.21 | 0.12 | -2.83 | 0.005 | 0.07 | 0.62 |
| Belgium/Nether | 0.34 | 0.14 | -2.71 | 0.007 | 0.16 | 0.74 |
| Other | 0.25 | 0.10 | -3.41 | 0.001 | 0.11 | 0.56 |
| Age | 0.83 | 0.14 | -1.12 | 0.263 | 0.61 | 1.15 |
| Education | 1.33 | 0.20 | 1.83 | 0.068 | 0.98 | 1.79 |
| CA type | | | | | | |
| Cleft Lip | 1.79 | 0.46 | 2.29 | 0.022 | 1.09 | 2.96 |
| Spina bifida | 1.19 | 0.42 | 0.49 | 0.622 | 0.60 | 2.38 |
| Down syndrome | 0.97 | 0.29 | -0.09 | 0.927 | 0.54 | 1.75 |
| DS + CHD | 1.05 | 0.49 | 0.1 | 0.918 | 0.42 | 2.63 |
| cons | 0.40 | 0.18 | -2.06 | 0.04 | 0.17 | 0.96 |

Table 2 Logistic regression model output for cancelled/postponed surgeries

CHD – congenital heart defect; CA – congenital anomaly. Comparator groups were Poland for country, and CHD for CA type

| | | Standard | | | | |
|------------------|------------|----------|-------|-------|---------------|----------|
| Tests/procedures | Odds ratio | error | Z | P> z | [95% conf. ir | nterval] |
| Country | | | | | | |
| UK | 1.08 | 0.27 | 0.3 | 0.767 | 0.66 | 1.74 |
| Germany | 0.11 | 0.04 | -6.55 | 0.000 | 0.06 | 0.21 |
| Croatia | 0.29 | 0.09 | -3.9 | 0.000 | 0.15 | 0.54 |
| Italy | 0.61 | 0.20 | -1.51 | 0.132 | 0.33 | 1.16 |
| Belgium/Nether | 0.15 | 0.05 | -5.31 | 0.000 | 0.07 | 0.30 |
| Other | 0.39 | 0.10 | -3.69 | 0.000 | 0.23 | 0.64 |
| | | | | | | |
| Age | 1.18 | 0.15 | 1.32 | 0.185 | 0.92 | 1.52 |
| Education | 1.15 | 0.14 | 1.16 | 0.246 | 0.91 | 1.47 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.45 | 0.31 | 1.75 | 0.08 | 0.96 | 2.21 |
| Spina bifida | 2.78 | 0.74 | 3.86 | 0.000 | 1.65 | 4.67 |
| Down syndrome | 2.40 | 0.52 | 4.05 | 0.000 | 1.57 | 3.66 |
| DS + CHD | 1.69 | 0.60 | 1.47 | 0.142 | 0.84 | 3.41 |
| | | | | | | |
| _cons | 0.65 | 0.23 | -1.23 | 0.218 | 0.33 | 1.29 |

CHD – congenital heart defect; CA – congenital anomaly.

| Table 4 Logistic regression | gression model output for problems accessing medication (a little-very) | | |
|-----------------------------|---|--|--|
| Accessing | gression model output for problems accessing medication (a little-very) | | |

| Accessing | | Standard | | | | | |
|---------------------------|---|----------|-------|-------|------------|-----------|--|
| medication | Odds ratio | error | Z | P> z | [95% conf. | interval] | |
| Country | | | | | | | |
| UK | 1.42 | 0.36 | 1.39 | 0.165 | 0.87 | 2.32 | |
| Germany | 0.14 | 0.07 | -3.97 | 0.000 | 0.06 | 0.38 | |
| Croatia | 0.08 | 0.06 | -3.37 | 0.001 | 0.02 | 0.35 | |
| Italy | 0.30 | 0.15 | -2.38 | 0.017 | 0.11 | 0.81 | |
| Belgium/Nether | 0.43 | 0.17 | -2.17 | 0.030 | 0.20 | 0.92 | |
| Other | 0.16 | 0.07 | -4.07 | 0.000 | 0.07 | 0.39 | |
| | | | | | | | |
| Age | 0.91 | 0.13 | -0.65 | 0.518 | 0.69 | 1.21 | |
| Education | 0.87 | 0.13 | -0.95 | 0.340 | 0.65 | 1.16 | |
| | | | | | | | |
| CA type | | | | | | | |
| Cleft Lip | 0.35 | 0.10 | -3.66 | 0.000 | 0.20 | 0.61 | |
| Spina bifida | 0.71 | 0.20 | -1.23 | 0.218 | 0.41 | 1.23 | |
| Down syndrome | 0.58 | 0.14 | -2.23 | 0.026 | 0.36 | 0.94 | |
| DS + CHD | 0.36 | 0.16 | -2.37 | 0.018 | 0.15 | 0.84 | |
| | | | | | | | |
| cons | 1.24 | 0.49 | 0.56 | 0.578 | 0.58 | 2.68 | |
| CHD – congenital heart de | CHD – congenital heart defect; CA – congenital anomaly. | | | | | | |

Comparator groups were Poland for country, and CHD for CA type

| Face-to-face | | Standard | | | | |
|----------------|------------|----------|-------|-------|--------------|----------|
| rescheduled | Odds ratio | error | z | P> z | [95% conf. i | nterval] |
| Country | | | | | | |
| UK | 2.84 | 0.88 | 3.38 | 0.001 | 1.55 | 5.20 |
| Germany | 0.12 | 0.04 | -7.17 | 0.000 | 0.07 | 0.21 |
| Croatia | 0.31 | 0.10 | -3.76 | 0.000 | 0.17 | 0.57 |
| Italy | 0.21 | 0.07 | -4.64 | 0.000 | 0.11 | 0.40 |
| Belgium/Nether | 0.18 | 0.06 | -5.34 | 0.000 | 0.10 | 0.34 |
| Other | 0.41 | 0.10 | -3.53 | 0.000 | 0.25 | 0.67 |
| | | | | | | |
| Age | 1.15 | 0.15 | 1.07 | 0.284 | 0.89 | 1.48 |
| Education | 1.06 | 0.14 | 0.49 | 0.626 | 0.83 | 1.36 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.37 | 0.29 | 1.51 | 0.131 | 0.91 | 2.07 |
| Spina bifida | 2.82 | 0.75 | 3.93 | 0.000 | 1.68 | 4.74 |
| Down syndrome | 3.29 | 0.71 | 5.47 | 0.000 | 2.14 | 5.03 |
| DS + CHD | 5.39 | 2.31 | 3.94 | 0.000 | 2.33 | 12.46 |
| | | | | | | |
| _cons | 0.95 | 0.33 | -0.16 | 0.873 | 0.48 | 1.88 |

Table 5 Logistic regression model output for face-to-face appointments re-scheduled as virtual

CHD – congenital heart defect; CA – congenital anomaly.

| Quality of virtual | | | | - | | |
|--------------------|------------|----------|-------|-------|------------|-----------|
| appointments | | Standard | | | | |
| (poor) | Odds ratio | error | Z | P> z | [95% conf. | interval] |
| Country | | | | | | |
| UK | 0.44 | 0.12 | -2.89 | 0.004 | 0.26 | 0.77 |
| Germany | 1.00+ | (empty) | | | | |
| Croatia | 0.32 | 0.18 | -1.99 | 0.047 | 0.11 | 0.98 |
| Italy | 0.62 | 0.35 | -0.84 | 0.403 | 0.21 | 1.89 |
| Belgium/Nether | 0.09 | 0.09 | -2.35 | 0.019 | 0.01 | 0.67 |
| Other | 0.46 | 0.18 | -1.98 | 0.048 | 0.22 | 0.99 |
| | | | | | | |
| Age | 0.95 | 0.15 | -0.35 | 0.724 | 0.70 | 1.28 |
| Education | 0.56 | 0.09 | -3.59 | 0 | 0.41 | 0.77 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 0.72 | 0.21 | -1.11 | 0.267 | 0.40 | 1.28 |
| Spina bifida | 0.65 | 0.22 | -1.29 | 0.196 | 0.33 | 1.25 |
| Down syndrome | 0.71 | 0.19 | -1.3 | 0.192 | 0.42 | 1.19 |
| DS + CHD | 0.65 | 0.29 | -0.97 | 0.333 | 0.28 | 1.54 |
| | | | | | | |
| cons | 2.44 | 1.08 | 2.01 | 0.044 | 1.02 | 5.82 |

Table 6 Logistic regression model output for the quality of virtual appointments (poor)

[†]0 participants in Germany rated virtual appointments as poor

 $\mathsf{CHD}-\mathsf{congenital}$ heart defect; $\mathsf{CA}-\mathsf{congenital}$ anomaly. Comparator groups were Poland for country, and CHD for CA type

| | | Standard | | | | |
|-----------------|------------|----------|-------|-------|--------------|-----------|
| Support from GP | Odds ratio | error | Z | P> z | [95% conf. i | interval] |
| Country | | | | | | |
| UK | 0.97 | 0.26 | -0.1 | 0.920 | 0.57 | 1.65 |
| Germany | 16.28 | 6.08 | 7.47 | 0.000 | 7.83 | 33.86 |
| Croatia | 1.99 | 0.59 | 2.32 | 0.020 | 1.11 | 3.56 |
| Italy | 2.29 | 0.76 | 2.5 | 0.013 | 1.19 | 4.38 |
| Belgium/Nether | 4.05 | 1.33 | 4.27 | 0.000 | 2.13 | 7.69 |
| Other | 2.38 | 0.67 | 3.09 | 0.002 | 1.37 | 4.13 |
| | | | | | | |
| Age | 0.90 | 0.12 | -0.85 | 0.395 | 0.69 | 1.16 |
| Education | 0.95 | 0.12 | -0.43 | 0.669 | 0.73 | 1.22 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 0.76 | 0.18 | -1.15 | 0.251 | 0.48 | 1.21 |
| Spina bifida | 1.38 | 0.38 | 1.16 | 0.247 | 0.80 | 2.36 |
| Down syndrome | 1.14 | 0.25 | 0.61 | 0.540 | 0.74 | 1.76 |
| DS + CHD | 1.45 | 0.56 | 0.97 | 0.333 | 0.68 | 3.07 |
| | | | | | | |
| _cons | 0.46 | 0.17 | -2.16 | 0.031 | 0.23 | 0.93 |

| Table 6 Logistic regression model output for satisfaction with | th current from conoral practitionar |
|--|--------------------------------------|
| Table b Logistic regression model output for satisfaction wi | In Support from general practitioner |
| | |

CHD – congenital heart defect; CA – congenital anomaly.

| 1 | | | | | |
|------------|---|--|--|---|---|
| Odds ratio | error | z | P> z | [95% conf. i | nterval] |
| | | | | | |
| 1.38 | 0.33 | 1.32 | 0.188 | 0.86 | 2.21 |
| 12.10 | 4.46 | 6.76 | 0.000 | 5.87 | 24.92 |
| 1.86 | 0.53 | 2.14 | 0.032 | 1.05 | 3.26 |
| 0.94 | 0.34 | -0.17 | 0.868 | 0.46 | 1.92 |
| 3.09 | 0.90 | 3.87 | 0.000 | 1.75 | 5.48 |
| 1.75 | 0.45 | 2.18 | 0.029 | 1.06 | 2.89 |
| | | | | | |
| 1.00 | 0.13 | 0.03 | 0.972 | 0.79 | 1.28 |
| 1.04 | 0.13 | 0.34 | 0.735 | 0.82 | 1.34 |
| | | | | | |
| | | | | | |
| 1.10 | 0.24 | 0.43 | 0.664 | 0.72 | 1.67 |
| 0.94 | 0.25 | -0.22 | 0.825 | 0.57 | 1.57 |
| 0.55 | 0.12 | -2.8 | 0.005 | 0.36 | 0.83 |
| 1.06 | 0.39 | 0.16 | 0.876 | 0.51 | 2.18 |
| | | | | | |
| 0.49 | 0.17 | -2.08 | 0.038 | 0.25 | 0.96 |
| | 1.38 12.10 1.86 0.94 3.09 1.75 1.00 1.04 1.10 0.94 0.55 1.06 0.49 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |

Table 7 Logistic regression model output for satisfaction with support from specialist doctor/nurse

CHD – congenital heart defect; CA – congenital anomaly.

Comparator groups were Poland for country, and CHD for CA type

| Support from | | Standard | | | | |
|----------------|------------|----------|-------|-------|---------------|----------|
| schools | Odds ratio | error | Z | P> z | [95% conf. ii | nterval] |
| Country | | | | | | |
| UK | 2.40 | 0.80 | 2.63 | 0.009 | 1.25 | 4.61 |
| Germany | 1.76 | 0.90 | 1.11 | 0.267 | 0.65 | 4.81 |
| Croatia | 0.63 | 0.37 | -0.79 | 0.431 | 0.19 | 2.01 |
| Italy | 1.96 | 0.74 | 1.78 | 0.076 | 0.93 | 4.11 |
| Belgium/Nether | 1.54 | 0.62 | 1.07 | 0.287 | 0.70 | 3.41 |
| Other | 1.32 | 0.49 | 0.75 | 0.455 | 0.64 | 2.75 |
| Age | 0.96 | 0.19 | -0.23 | 0.822 | 0.65 | 1.41 |
| Education | 0.92 | 0.16 | -0.46 | 0.645 | 0.66 | 1.30 |
| CA type | | | | | | |
| Cleft Lip | 1.02 | 0.35 | 0.05 | 0.959 | 0.52 | 1.99 |
| Spina bifida | 1.37 | 0.50 | 0.85 | 0.393 | 0.67 | 2.81 |
| Down syndrome | 1.64 | 0.51 | 1.62 | 0.106 | 0.90 | 3.00 |
| DS + CHD | 1.53 | 0.89 | 0.74 | 0.459 | 0.49 | 4.76 |
| cons | 0.37 | 0.21 | -1.76 | 0.078 | 0.12 | 1.12 |

CHD – congenital heart defect; CA – congenital anomaly.

| Support from | | Standard | | | | |
|----------------|------------|----------|-------|-------|---------------|---------|
| partner | Odds ratio | error | Z | P> z | [95% conf. in | terval] |
| Country | | | | | | |
| UK | 1.62 | 0.42 | 1.87 | 0.062 | 0.98 | 2.70 |
| Germany | 3.61 | 1.62 | 2.86 | 0.004 | 1.50 | 8.70 |
| Croatia | 1.79 | 0.58 | 1.79 | 0.073 | 0.95 | 3.38 |
| Italy | 1.09 | 0.37 | 0.25 | 0.804 | 0.56 | 2.13 |
| Belgium/Nether | 0.84 | 0.24 | -0.64 | 0.523 | 0.48 | 1.45 |
| Other | 1.01 | 0.27 | 0.02 | 0.981 | 0.60 | 1.69 |
| | | | | | | |
| Age | 1.04 | 0.13 | 0.29 | 0.770 | 0.81 | 1.32 |
| Education | 1.01 | 0.13 | 0.06 | 0.954 | 0.79 | 1.28 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.63 | 0.36 | 2.22 | 0.026 | 1.06 | 2.50 |
| Spina bifida | 1.70 | 0.48 | 1.88 | 0.061 | 0.98 | 2.97 |
| Down syndrome | 1.11 | 0.23 | 0.51 | 0.607 | 0.74 | 1.66 |
| DS + CHD | 1.15 | 0.41 | 0.38 | 0.702 | 0.57 | 2.32 |
| | | | | | | |
| _cons | 1.71 | 0.59 | 1.53 | 0.125 | 0.86 | 3.37 |

Table 9 Logistic regression model output for satisfaction with support from partner

CHD – congenital heart defect; CA – congenital anomaly.

Comparator groups were Poland for country, and CHD for CA type

| Support from | | Standard | | | | <u> </u> |
|----------------|------------|----------|-------|-------|---------------|----------|
| friends/family | Odds ratio | error | z | P> z | [95% conf. in | terval] |
| Country | | | | | | |
| UK | 0.62 | 0.13 | -2.22 | 0.027 | 0.40 | 0.95 |
| Germany | 1.77 | 0.55 | 1.81 | 0.070 | 0.96 | 3.27 |
| Croatia | 1.13 | 0.32 | 0.44 | 0.659 | 0.65 | 1.95 |
| Italy | 0.56 | 0.17 | -1.89 | 0.059 | 0.30 | 1.02 |
| Belgium/Nether | 0.61 | 0.16 | -1.86 | 0.062 | 0.36 | 1.03 |
| Other | 0.71 | 0.17 | -1.44 | 0.151 | 0.44 | 1.14 |
| | | | | | | |
| Age | 0.89 | 0.10 | -1.08 | 0.280 | 0.71 | 1.10 |
| Education | 1.12 | 0.13 | 1.03 | 0.303 | 0.90 | 1.40 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.15 | 0.23 | 0.71 | 0.478 | 0.78 | 1.69 |
| Spina bifida | 0.92 | 0.22 | -0.34 | 0.731 | 0.57 | 1.48 |
| Down syndrome | 1.11 | 0.21 | 0.54 | 0.586 | 0.77 | 1.60 |
| DS + CHD | 1.17 | 0.38 | 0.47 | 0.636 | 0.62 | 2.21 |
| | | | | | | |
| _cons | 1.56 | 0.48 | 1.43 | 0.151 | 0.85 | 2.86 |

 Table 10 Logistic regression model output for satisfaction with support from friends and family

CHD – congenital heart defect; CA – congenital anomaly.

| Support from | Standard | | | | | |
|----------------|------------|-------|-------|-------|----------------------|------|
| other parents | Odds ratio | error | Z | P> z | [95% conf. interval] | |
| Country | | | | | | |
| UK | 0.52 | 0.13 | -2.6 | 0.009 | 0.32 | 0.85 |
| Germany | 0.77 | 0.32 | -0.64 | 0.520 | 0.34 | 1.73 |
| Croatia | 0.89 | 0.27 | -0.4 | 0.693 | 0.49 | 1.60 |
| Italy | 0.39 | 0.15 | -2.47 | 0.013 | 0.18 | 0.82 |
| Belgium/Nether | 0.25 | 0.10 | -3.45 | 0.001 | 0.11 | 0.55 |
| Other | 0.64 | 0.19 | -1.54 | 0.122 | 0.36 | 1.13 |
| | | | | | | |
| Age | 0.94 | 0.13 | -0.47 | 0.636 | 0.71 | 1.23 |
| Education | 1.06 | 0.14 | 0.46 | 0.647 | 0.82 | 1.39 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.60 | 0.39 | 1.93 | 0.054 | 0.99 | 2.57 |
| Spina bifida | 0.73 | 0.22 | -1.03 | 0.303 | 0.41 | 1.32 |
| Down syndrome | 1.07 | 0.24 | 0.32 | 0.749 | 0.70 | 1.65 |
| DS + CHD | 1.25 | 0.49 | 0.57 | 0.572 | 0.58 | 2.68 |
| | | | | | | |
| _cons | 1.84 | 0.69 | 1.64 | 0.101 | 0.89 | 3.82 |

Table 11 Logistic regression model output for satisfaction with support from other parents

CHD – congenital heart defect; CA – congenital anomaly.

Comparator groups were Poland for country, and CHD for CA type

| Support from patient | | Standard | | | | |
|-------------------------|------------|----------|-------|-------|----------------------|------|
| organisations | Odds ratio | error | z | P> z | [95% conf. interval] | |
| Country | | | | | | |
| UK | 0.48 | 0.13 | -2.76 | 0.006 | 0.28 | 0.81 |
| Germany | 1.14 | 0.52 | 0.28 | 0.780 | 0.46 | 2.81 |
| Croatia | 0.45 | 0.16 | -2.21 | 0.027 | 0.22 | 0.91 |
| Italy | 0.39 | 0.15 | -2.4 | 0.016 | 0.18 | 0.84 |
| Belgium/Nether | 0.12 | 0.08 | -3.34 | 0.001 | 0.03 | 0.41 |
| Other | 0.49 | 0.15 | -2.34 | 0.019 | 0.27 | 0.89 |
| | | | | | | |
| Age | 0.96 | 0.15 | -0.24 | 0.808 | 0.71 | 1.31 |
| Education | 0.99 | 0.15 | -0.09 | 0.931 | 0.74 | 1.32 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 1.46 | 0.40 | 1.4 | 0.162 | 0.86 | 2.50 |
| Spina bifida | 0.70 | 0.23 | -1.07 | 0.284 | 0.36 | 1.34 |
| Down syndrome | 1.03 | 0.25 | 0.13 | 0.899 | 0.64 | 1.66 |
| DS + CHD | 1.26 | 0.51 | 0.57 | 0.572 | 0.57 | 2.81 |
| | | | | | | |
| _cons | 1.33 | 0.55 | 0.69 | 0.488 | 0.59 | 2.99 |

CHD – congenital heart defect; CA – congenital anomaly.

| Overall more | Standard | | | | | |
|----------------|------------|-------|-------|-------|----------------------|------|
| support needed | Odds ratio | error | z | P> z | [95% conf. interval] | |
| Country | | | | | | |
| UK | 0.75 | 0.18 | -1.18 | 0.236 | 0.47 | 1.21 |
| Germany | 0.55 | 0.17 | -1.98 | 0.048 | 0.30 | 0.99 |
| Croatia | 0.38 | 0.14 | -2.69 | 0.007 | 0.18 | 0.77 |
| Italy | 0.54 | 0.19 | -1.72 | 0.086 | 0.27 | 1.09 |
| Belgium/Nether | 0.22 | 0.10 | -3.38 | 0.001 | 0.09 | 0.53 |
| Other | 0.28 | 0.10 | -3.59 | 0.000 | 0.14 | 0.56 |
| | | | | | | |
| Age | 1.02 | 0.13 | 0.13 | 0.898 | 0.79 | 1.30 |
| Education | 0.92 | 0.11 | -0.64 | 0.520 | 0.72 | 1.18 |
| | | | | | | |
| CA type | | | | | | |
| Cleft Lip | 0.53 | 0.13 | -2.68 | 0.007 | 0.34 | 0.85 |
| Spina bifida | 0.86 | 0.23 | -0.57 | 0.569 | 0.50 | 1.46 |
| Down syndrome | 1.03 | 0.21 | 0.14 | 0.889 | 0.69 | 1.54 |
| DS + CHD | 1.04 | 0.36 | 0.11 | 0.914 | 0.53 | 2.04 |
| | | | | | | |
| _cons | 0.54 | 0.19 | -1.76 | 0.078 | 0.28 | 1.07 |

 Table 13 Logistic regression model output for 'overall need for more support'

CHD – congenital heart defect; CA – congenital anomaly.